Chris Schott
Stock Analyst at JP Morgan
(3.53)
# 841
Out of 4,868 analysts
130
Total ratings
56.98%
Success rate
2.31%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $510.45 | +56.72% | 7 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $16.90 | +36.09% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $126.52 | +38.32% | 4 | May 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $109.04 | +19.22% | 6 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $7.81 | +53.75% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $184.73 | +8.27% | 2 | Nov 13, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $518.89 | +10.81% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $156.53 | +46.94% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $765.42 | +43.71% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $9.72 | +105.76% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $26.43 | +55.16% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $34.65 | +21.21% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $290.54 | -7.07% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $23.90 | +42.29% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $79.49 | +57.25% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $8.80 | +59.09% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.74 | +1,386.49% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $13.42 | +49.03% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.07 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $46.88 | +66.40% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $4.09 | +23,155.81% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.11 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $24.11 | +107.38% | 3 | Nov 2, 2018 |
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $510.45
Upside: +56.72%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $16.90
Upside: +36.09%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $126.52
Upside: +38.32%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $109.04
Upside: +19.22%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.81
Upside: +53.75%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $184.73
Upside: +8.27%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $518.89
Upside: +10.81%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $156.53
Upside: +46.94%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $765.42
Upside: +43.71%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.72
Upside: +105.76%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $26.43
Upside: +55.16%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $34.65
Upside: +21.21%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $290.54
Upside: -7.07%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $23.90
Upside: +42.29%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $79.49
Upside: +57.25%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $8.80
Upside: +59.09%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.74
Upside: +1,386.49%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $13.42
Upside: +49.03%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.07
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $46.88
Upside: +66.40%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $4.09
Upside: +23,155.81%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.11
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $24.11
Upside: +107.38%